Lipidation of NOD2 agonists with adamantane and stearoyl moieties differentially regulates their In vivo adjuvant activity
Povzetek
NOD2 is an innate immune receptor that constitutes an important target for the development of small molecule immunopotentiators with great potential to be used as vaccine adjuvants. We report here the results of an in vivo study of the adjuvant properties of a desmuramylpeptide NOD2 agonist SG29 and its lipidated analogs featuring an adamantyl moiety or a stearoyl group. These compounds have been synthesized, incorporated into liposomes, and evaluated for their in vivo adjuvant activity. The characterization of liposome formulations of examined compounds revealed that their size increased in comparison to that of empty liposomes. The introduction of a stearoyl or an adamantane lipophilic anchor into the structure of SG29, to produce SG115 and ZSB63, respectively, substantially improved the in vivo adjuvant activity. Of note, the attachment of the stearoyl moiety produced a Th2-biased immune response, while the incorporation of the adamantyl moiety greatly enhanced the production of total IgG but mostly augmented the production of IgG2a antibodies, which indicated a shift toward a Th1 immune response. The identified bona fide capacity of ZSB63 to initiate a cellular immune response thus highlights its untapped potential as an alternative vaccine adjuvant.
Ključne besede
agonisti NOD2;adjuvans za cepivo;adamantan;imunopotenciatorji;desmuramilpeptidi;NOD2 agonist;vaccine adjuvant;adamantane;immunopotentiators;desmuramylpeptides;
Podatki
| Jezik: | Angleški jezik |
|---|---|
| Leto izida: | 2022 |
| Tipologija: | 1.01 - Izvirni znanstveni članek |
| Organizacija: | UL FFA - Fakulteta za farmacijo |
| UDK: | 615.4:54:616-097 |
| COBISS: |
133033219
|
| ISSN: | 1999-4923 |
| Št. ogledov: | 15 |
| Št. prenosov: | 0 |
| Ocena: | 0 (0 glasov) |
| Metapodatki: |
|
Ostali podatki
| Sekundarni jezik: | Slovenski jezik |
|---|---|
| Sekundarne ključne besede: | Imunski odziv;Farmacevtska kemija; |
| Vrsta dela (COBISS): | Članek v reviji |
| Strani: | 9 str. |
| Letnik: | ǂVol. ǂ14 |
| Zvezek: | ǂiss. ǂ12, art. 2755 |
| Čas izdaje: | 2022 |
| DOI: | 10.3390/pharmaceutics14122755 |
| ID: | 17361117 |
Priporočena dela:
Lipidation of NOD2 agonists with adamantane and stearoyl moieties differentially regulates their In vivo adjuvant activity
2022,
ni podatka o podnaslovu
Nucleotide-Binding oligomerization domain 1/Toll-like receptor 4 co-engagement promotes non-specific immune response against K562 cancer cells
2022,
ni podatka o podnaslovu
Structural fine-tuning of desmuramylpeptide NOD2 agonists defines their in vivo adjuvant activity
2021,
ni podatka o podnaslovu
Harnessing the untapped potential of NOD ligands for cancer immunotherapy
2019,
ni podatka o podnaslovu
Modificirane dendritične celice kot cepivo proti raku
2020,
diplomsko delo